MedTrace
Denmark - HørsholmBiotechnology
Focus: MedTrace is a Danish biotechnology company specializing in organ perfusion imaging, with a clinical-stage focus on cardiovascular and neurological applications. The company operates at a modest scale with a highly concentrated pipeline in Phase 3 development.
Profile data last refreshed 6h ago · AI intelligence enriched 3w ago
Open Jobs
2
Should You Work at MedTrace?
AI assessmentMedTrace is a high-risk, high-potential microcap suitable only for mission-driven scientists seeking early-stage exposure; not recommended for professionals prioritizing stability or growth.
Why Work Here
- Lead role in an emerging organ perfusion imaging platform with Phase 3 clinical validation in coronary artery disease, a multi-billion-dollar diagnostic market.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
[O-15]-Water PET Myocardial Perfusion Imaging
Coronary Artery DiseaseClinical Trials (1)
NCT05134012RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
Phase 3Help build intelligence for MedTrace
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.